FDA deals Takeda pipeline setback

Share this article:

The FDA recommended that Takeda halt high-dose clinical studies of its TAK-475 cholesterol drug due to possible liver side effects, asking for additional data on the drug.
 
News of the setback sent shares of Takeda tumbling 12%, to $61.59 on the Tokyo Stock Exchange.

Financial firm Mitsubishi UFJ Securities lowered its rating on Takeda from “3” to “2,” predicting that the overseas launch of TAK-475 could be delayed by more than two years.

Takeda had planned to seek approval for the drug this April and hoped TAK-475 could help replace sales of its best-selling diabetes drug, Actos, when that drug's patent expires in 2011. Actos, with global sales of $2.8 billion, accounted for a quarter of Takeda's revenue last year.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.